Literature DB >> 24710577

Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Alexander C J van Akkooi1, Alexander M M Eggermont2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24710577     DOI： 10.1038/nrclinonc.2014.64

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Prognostic false-positivity of the sentinel node in melanoma.

Authors:  J Meirion Thomas
Journal:  Nat Clin Pract Oncol       Date:  2008-01

Review 2.  Cutaneous melanoma.

Authors:  Alexander M M Eggermont; Alan Spatz; Caroline Robert
Journal:  Lancet       Date:  2013-09-19       Impact factor: 79.321

3.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

Authors:  Alexander M M Eggermont; Stefan Suciu; Alessandro Testori; Wim H Kruit; Jeremy Marsden; Cornelis J Punt; Mario Santinami; François Salès; Dirk Schadendorf; Poulam Patel; Reinhard Dummer; Caroline Robert; Ulrich Keilholz; Antoine Yver; Alan Spatz
Journal:  Eur J Cancer       Date:  2011-11-05       Impact factor: 9.162

4.  Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.

Authors:  L Altstein; G Li
Journal:  Biometrics       Date:  2013-02-05       Impact factor: 2.571

5.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

6.  Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

Authors:  Alexander M M Eggermont; Stefan Suciu; Alessandro Testori; Mario Santinami; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Reinhard Dummer; Caroline Robert; Dirk Schadendorf; Poulam M Patel; Gaetan de Schaetzen; Alan Spatz; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

7.  Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?

Authors:  Christiane A Voit; Alexander C J van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Paul I M Schmitz; Wolfram Sterry; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

8.  Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma.

Authors:  Christiane Voit; Alexander C J Van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Katharina Kowalczyk; Joachim C Roewert; Wolfram Sterry; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

9.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.

Authors:  Augustinus P T van der Ploeg; Alexander C J van Akkooi; Piotr Rutkowski; Zbigniew I Nowecki; Wanda Michej; Angana Mitra; Julia A Newton-Bishop; Martin Cook; Iris M C van der Ploeg; Omgo E Nieweg; Mari F C M van den Hout; Paul A M van Leeuwen; Christiane A Voit; Francesco Cataldo; Alessandro Testori; Caroline Robert; Harald J Hoekstra; Cornelis Verhoef; Alain Spatz; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544
  10 in total
  4 in total

1.  SLNB in melanoma-DFS a true and cost-effective benefit?

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

2.  MSLT-I-response of clinical trial investigators.

Authors:  Mark B Faries; Alistair J Cochran; John F Thompson
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

3.  Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine.

Authors:  David Olmeda; Daniela Cerezo-Wallis; Erica Riveiro-Falkenbach; Paula C Pennacchi; Marta Contreras-Alcalde; Nuria Ibarz; Metehan Cifdaloz; Xavier Catena; Tonantzin G Calvo; Estela Cañón; Direna Alonso-Curbelo; Javier Suarez; Lisa Osterloh; Osvaldo Graña; Francisca Mulero; Diego Megías; Marta Cañamero; Jorge L Martínez-Torrecuadrada; Chandrani Mondal; Julie Di Martino; David Lora; Inés Martinez-Corral; J Javier Bravo-Cordero; Javier Muñoz; Susana Puig; Pablo Ortiz-Romero; José L Rodriguez-Peralto; Sagrario Ortega; María S Soengas
Journal:  Nature       Date:  2017-06-28       Impact factor: 49.962

Review 4.  Heterogeneity of tumor lymphangiogenesis: Progress and prospects.

Authors:  Xueting Hu; Jincai Luo
Journal:  Cancer Sci       Date:  2018-08-23       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.